Market Cap 251.22M
Revenue (ttm) 236.20M
Net Income (ttm) -5.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2.27%
Debt to Equity Ratio 1.98
Volume 6,450,100
Avg Vol 5,369,150
Day's Range N/A - N/A
Shares Out 277.11M
Stochastic %K 66%
Beta 0.26
Analysts Strong Sell
Price Target $3.80

Company Profile

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 617 871 2098
Fax: 617 871 2099
Address:
245 First Street, Suite 1400, Cambridge, United States
Invest2live
Invest2live Aug. 24 at 4:22 AM
$CPIX 339% already; congrats 🪷🌟🌺 Checkout $AKBA and $QSI ; both have similar potential for longs.
1 · Reply
PharmaExpert
PharmaExpert Aug. 24 at 2:06 AM
$AKBA is it monday yet!🔥
0 · Reply
Thomasboy1
Thomasboy1 Aug. 24 at 1:02 AM
$AKBA looking forward to this week. I think we get a little bump maybe burn a few shorts. They panic easy and can turn n burn into a blaze! GL
1 · Reply
King_of_Bio
King_of_Bio Aug. 23 at 11:42 PM
$AKBA Ok...I dig
0 · Reply
Eagle510
Eagle510 Aug. 23 at 9:07 PM
$AKBA I like the BO discussions. Only way to get out of this mess. IMHO.
0 · Reply
MB76
MB76 Aug. 23 at 8:47 PM
$AKBA Look at the "majority" of the posts this weekend. All from the same CLOWN and his various accounts. WHY? HMMM, not getting my shares CLOWN!
0 · Reply
Paperglider
Paperglider Aug. 23 at 6:08 PM
$AKBA ACCOLADE - Tavneos trial in C3G (Amgen)
0 · Reply
Paperglider
Paperglider Aug. 23 at 5:57 PM
$AKBA https://pubmed.ncbi.nlm.nih.gov/39392695/ When preliminary results for Tavenos ACCOLADE trial in C3G were announced (Dec 2020), ChemoCentryx claimed "statistically significant eGFR improvement." When the final 2024/2025 publication came out, those secondary endpoints were NOT statistically significant. This is really bad for Amgen and now with EMA Tavenos withdrawal and FDA review. Medical literature now increasingly points towards upstream C3 inhibition (Ebribafusp's strategy) being superior to downstream C5a blockade (Tavneos's failed strategy). - Avacopan (C5a antagonist): ACCOLADE failed primary endpoint; zero histology improvement - Iptacopan (Factor B inhibitor): 45% proteinuria reduction; 2.5x C3 deposit reduction in Phase 2 - Pegcetacoplan (C3/C3b inhibitor): FDA approved 2023 for C3G - Ebribafusp (Tissue-targeted C3d + Factor H): Upstream mechanism; expected to succeed and the only one of its kind. Bottom-line, Amgen has almost COMPLETELY EXITED non-AAV kidney disease development.
0 · Reply
Noname2022
Noname2022 Aug. 23 at 5:48 PM
$AKBA Don’t forget, some of us actually do the work instead of repeating the herd narrative. With the exception of a few free thinkers in here… baaaaah.
0 · Reply
DrKennethNoisewater
DrKennethNoisewater Aug. 23 at 5:41 PM
$AKBA following voice, I believe the buyout thesis here is strengthening materially and the time to act for the parties with the most to gain is narrow (within 12 months). It’s my thesis that the two best suited acquirers are Amgen and CSL/Vifor and from my analysis believe CSL/Vifor will outbid as vafseo represents the highest strategic value to them. The main reasons are related to highest amount of synergy with current product portfolio (bundling discounts for LDOs with comprehensive anemia management basket), most leverage in negotiating pricing & driving uptake with DOs, the existing sales infrastructure, intimate knowledge of the market, and intimate knowledge of Vafseo, and most importantly potential lost revenue to mircera if Vafseo penetrates. My fair value acquisition cost to them today would be 5.50 or around 1.5billion market cap. This values pipeline at almost nothing, which can change instantly following upcoming readouts.
5 · Reply
Latest News on AKBA
Akebia Therapeutics Earnings Call Transcript: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 18 days ago

Akebia Therapeutics Earnings Call Transcript: Q2 2026


Akebia Therapeutics Earnings release: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 18 days ago

Akebia Therapeutics Earnings release: Q2 2026


Akebia Therapeutics Quarterly report: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 18 days ago

Akebia Therapeutics Quarterly report: Q2 2026


Akebia initiates ebribafusp basket trial

2026-08-03T12:20:30.000Z - 20 days ago

Akebia initiates ebribafusp basket trial


Akebia announces VOICE trial met predefined stopping criteria

2026-06-30T12:31:42.000Z - 7 weeks ago

Akebia announces VOICE trial met predefined stopping criteria


Akebia Therapeutics Transcript: AGM 2026

Jun 17, 2026, 10:00 AM EDT - 2 months ago

Akebia Therapeutics Transcript: AGM 2026


Akebia announces new Vafseo patent

2026-06-10T12:28:51.000Z - 2 months ago

Akebia announces new Vafseo patent


Akebia Therapeutics Earnings Call Transcript: Q1 2026

May 7, 2026, 8:00 AM EDT - 3 months ago

Akebia Therapeutics Earnings Call Transcript: Q1 2026


Akebia Therapeutics Earnings release: Q1 2026

May 7, 2026, 8:00 AM EDT - 3 months ago

Akebia Therapeutics Earnings release: Q1 2026


Akebia Therapeutics Quarterly report: Q1 2026

May 7, 2026, 8:00 AM EDT - 3 months ago

Akebia Therapeutics Quarterly report: Q1 2026


Akebia Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Akebia Therapeutics Proxy statement: Proxy filing


Akebia Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Akebia Therapeutics Proxy statement: Proxy filing


Akebia Therapeutics Proxy statement: Proxy filing

Apr 15, 2026, 8:00 AM EDT - 4 months ago

Akebia Therapeutics Proxy statement: Proxy filing


Akebia doses first participants in AKB-9090 trial

2026-04-13T12:52:17.000Z - 4 months ago

Akebia doses first participants in AKB-9090 trial


Akebia Therapeutics Transcript: R&D Day 2026

Apr 2, 2026, 10:00 AM EDT - 5 months ago

Akebia Therapeutics Transcript: R&D Day 2026


Akebia Therapeutics Slides: FY 2026

Apr 2, 2026, 10:00 AM EDT - 5 months ago

Akebia Therapeutics Slides: FY 2026


Akebia Therapeutics Slides: Corporate presentation

Feb 27, 2026, 6:00 AM EST - 6 months ago

Akebia Therapeutics Slides: Corporate presentation


Akebia Therapeutics Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:00 AM EST - 6 months ago

Akebia Therapeutics Earnings Call Transcript: Q4 2025


Akebia Therapeutics Annual report: Q4 2025

Feb 26, 2026, 8:00 AM EST - 6 months ago

Akebia Therapeutics Annual report: Q4 2025


Akebia Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 8:00 AM EST - 6 months ago

Akebia Therapeutics Earnings release: Q4 2025


Akebia price target lowered to $4 from $5 at BTIG

2026-02-25T12:25:29.000Z - 6 months ago

Akebia price target lowered to $4 from $5 at BTIG


Akebia price target lowered to $4 from $6 at Piper Sandler

2026-02-06T11:56:25.000Z - 7 months ago

Akebia price target lowered to $4 from $6 at Piper Sandler


Akebia announces corporate updates, 2026 pipeline outlook

2026-01-12T13:52:21.000Z - 7 months ago

Akebia announces corporate updates, 2026 pipeline outlook


Q32 Bio sells complement inhibitor ADX-097 to Akebia

2025-12-01T12:05:21.000Z - 9 months ago

Q32 Bio sells complement inhibitor ADX-097 to Akebia

QTTB


Akebia Announces Establishment of Rare Kidney Disease Pipeline

Dec 1, 2025, 7:00 AM EST - 9 months ago

Akebia Announces Establishment of Rare Kidney Disease Pipeline


Q32 Bio Sells Complement Inhibitor ADX-097

Dec 1, 2025, 7:00 AM EST - 9 months ago

Q32 Bio Sells Complement Inhibitor ADX-097

QTTB


Akebia Therapeutics Earnings Call Transcript: Q3 2025

Nov 10, 2025, 8:00 AM EST - 10 months ago

Akebia Therapeutics Earnings Call Transcript: Q3 2025


Akebia Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 8:00 AM EST - 10 months ago

Akebia Therapeutics Quarterly report: Q3 2025


Akebia Therapeutics Earnings release: Q3 2025

Nov 10, 2025, 8:00 AM EST - 10 months ago

Akebia Therapeutics Earnings release: Q3 2025


Akebia Therapeutics to Present at Upcoming Investor Conferences

Nov 4, 2025, 8:00 AM EST - 10 months ago

Akebia Therapeutics to Present at Upcoming Investor Conferences


Akebia price target lowered to $6 from $8 at H.C. Wainwright

2025-10-30T10:11:16.000Z - 10 months ago

Akebia price target lowered to $6 from $8 at H.C. Wainwright


Akebia Therapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Earnings Call Transcript: Q2 2025


Akebia Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Quarterly report: Q2 2025


Akebia Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Earnings release: Q2 2025


Akebia Therapeutics Slides: Corporate Presentation

Jun 30, 2025, 7:00 AM EDT - 1 year ago

Akebia Therapeutics Slides: Corporate Presentation


Akebia Therapeutics Earnings Call Transcript: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Earnings Call Transcript: Q1 2025


Akebia Therapeutics Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Quarterly report: Q1 2025


Akebia Therapeutics Earnings release: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Earnings release: Q1 2025


Akebia Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Proxy statement: Proxy Filing


Akebia Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Proxy statement: Proxy Filing


Akebia Therapeutics Earnings Call Transcript: Q4 2024

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Earnings Call Transcript: Q4 2024


Akebia Therapeutics Annual report: Q4 2024

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Annual report: Q4 2024


Akebia Therapeutics Earnings release: Q4 2024

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Earnings release: Q4 2024


Akebia Therapeutics Slides: Investor Presentation

Jan 21, 2025, 7:00 AM EST - 1 year ago

Akebia Therapeutics Slides: Investor Presentation


Akebia Therapeutics Slides: FY 2025

Jan 16, 2025, 10:30 AM EST - 1 year ago

Akebia Therapeutics Slides: FY 2025


Invest2live
Invest2live Aug. 24 at 4:22 AM
$CPIX 339% already; congrats 🪷🌟🌺 Checkout $AKBA and $QSI ; both have similar potential for longs.
1 · Reply
PharmaExpert
PharmaExpert Aug. 24 at 2:06 AM
$AKBA is it monday yet!🔥
0 · Reply
Thomasboy1
Thomasboy1 Aug. 24 at 1:02 AM
$AKBA looking forward to this week. I think we get a little bump maybe burn a few shorts. They panic easy and can turn n burn into a blaze! GL
1 · Reply
King_of_Bio
King_of_Bio Aug. 23 at 11:42 PM
$AKBA Ok...I dig
0 · Reply
Eagle510
Eagle510 Aug. 23 at 9:07 PM
$AKBA I like the BO discussions. Only way to get out of this mess. IMHO.
0 · Reply
MB76
MB76 Aug. 23 at 8:47 PM
$AKBA Look at the "majority" of the posts this weekend. All from the same CLOWN and his various accounts. WHY? HMMM, not getting my shares CLOWN!
0 · Reply
Paperglider
Paperglider Aug. 23 at 6:08 PM
$AKBA ACCOLADE - Tavneos trial in C3G (Amgen)
0 · Reply
Paperglider
Paperglider Aug. 23 at 5:57 PM
$AKBA https://pubmed.ncbi.nlm.nih.gov/39392695/ When preliminary results for Tavenos ACCOLADE trial in C3G were announced (Dec 2020), ChemoCentryx claimed "statistically significant eGFR improvement." When the final 2024/2025 publication came out, those secondary endpoints were NOT statistically significant. This is really bad for Amgen and now with EMA Tavenos withdrawal and FDA review. Medical literature now increasingly points towards upstream C3 inhibition (Ebribafusp's strategy) being superior to downstream C5a blockade (Tavneos's failed strategy). - Avacopan (C5a antagonist): ACCOLADE failed primary endpoint; zero histology improvement - Iptacopan (Factor B inhibitor): 45% proteinuria reduction; 2.5x C3 deposit reduction in Phase 2 - Pegcetacoplan (C3/C3b inhibitor): FDA approved 2023 for C3G - Ebribafusp (Tissue-targeted C3d + Factor H): Upstream mechanism; expected to succeed and the only one of its kind. Bottom-line, Amgen has almost COMPLETELY EXITED non-AAV kidney disease development.
0 · Reply
Noname2022
Noname2022 Aug. 23 at 5:48 PM
$AKBA Don’t forget, some of us actually do the work instead of repeating the herd narrative. With the exception of a few free thinkers in here… baaaaah.
0 · Reply
DrKennethNoisewater
DrKennethNoisewater Aug. 23 at 5:41 PM
$AKBA following voice, I believe the buyout thesis here is strengthening materially and the time to act for the parties with the most to gain is narrow (within 12 months). It’s my thesis that the two best suited acquirers are Amgen and CSL/Vifor and from my analysis believe CSL/Vifor will outbid as vafseo represents the highest strategic value to them. The main reasons are related to highest amount of synergy with current product portfolio (bundling discounts for LDOs with comprehensive anemia management basket), most leverage in negotiating pricing & driving uptake with DOs, the existing sales infrastructure, intimate knowledge of the market, and intimate knowledge of Vafseo, and most importantly potential lost revenue to mircera if Vafseo penetrates. My fair value acquisition cost to them today would be 5.50 or around 1.5billion market cap. This values pipeline at almost nothing, which can change instantly following upcoming readouts.
5 · Reply
trader20201414
trader20201414 Aug. 23 at 3:24 PM
$AKBA facts time: The biggest bear case for Akebia is that Auryxia is falling off a cliff while Vafseo isn’t growing fast enough to replace it. Meanwhile, Akebia is still losing money, burning cash, and could face dilution. And its clinical pipeline is a huge risk—praliciguat is only in Phase 2 for FSGS, while AKB-097 is still heading into Phase 2, meaning these programs could easily fail to show efficacy or hit safety/regulatory problems. Basically, the old drug is dying faster than the new drug is growing, while the future pipeline is still a big gamble. And that ladies and gentlemen why the Stock is below $1. Its not manipulation, its just math 🤣
3 · Reply
USAEquityResearch
USAEquityResearch Aug. 23 at 11:13 AM
$AKBA 📊 USAEquityResearch ▼ 0.91 (-1.31%) Trend: Bearish 📉 RSI (14): 19.5 — oversold, potential bounce territory MACD: bearish, below signal line Volume: normal 📌 Key Levels Resistance: 1.35 | Support: 0.84 20-MA: 1.05 | 50-MA: 1.14 💼 Fundamentals Mkt Cap: $251.22M FCF: $33.62M (0.12/sh) Total Debt: $199.19M D/E: 796.18 📉 Options (exp 2026-09-18) ATM IV: 103.1% | Skew: -18.8% (call-heavy) P/C Ratio: 0.03 🐂 Bullish lean Max Pain: 1.00 Call wall: 1.00 Educational content only. Not financial advice. Full data, options chain & financials: https://usaequityresearch.com/stocks/AKBA
0 · Reply
TheGreedyGrinch
TheGreedyGrinch Aug. 23 at 10:44 AM
$AKBA @KarlDieGlatze Karl should be ashamed of himself. There's investors who have been trapped in this stock for over 10 years now and he have the audacity to post ,"Be patient". Investors have shown more than enough of patients. This management is all about feed their own pockets and have never cared about share holders. So Karl, stop trading with emotions. Looking at past practices over the last 5 years shows the future isn't so bright for akba as long as the same greedy management remains in office.
1 · Reply
KarlDieGlatze
KarlDieGlatze Aug. 23 at 1:16 AM
$AKBA Be patient, my fellow Akebians. My work with Amgen apprising them of the progress and massive opportunity taking place in Akebia requiring their RESOURCES will NOT BE LOST. God in Heaven guarantees this.
0 · Reply
Noname2022
Noname2022 Aug. 22 at 10:12 PM
0 · Reply
trader20201414
trader20201414 Aug. 22 at 8:26 PM
$AKBA facts time: Vasfeo still has a very long way to go to justify a $100 million annual revenue target, especially with Arixuya continuing to decline. At an average price of $2.X,000 per year, Vasfeo would need roughly 50,000 paying customers to generate $100 million annually, or about $25 million per quarter. That’s a massive gap to close, particularly if the broader business is seeing declining revenue from Arixuya. With the entire company’s valuation being supported by expectations of future growth, the current valuation looks increasingly difficult to justify unless Vasfeo can show a significant acceleration in customers, revenue, and overall business performance.
5 · Reply
TheGreedyGrinch
TheGreedyGrinch Aug. 22 at 5:54 PM
$AKBA @Mr_Pithy I'm flattered that someone would think so highly of me.
0 · Reply
Magic_Money
Magic_Money Aug. 22 at 4:47 PM
$AKBA Vadadustat = less hospital visits and less cost associated with hospitalizations. Extends lives of patients. Improved hemoglobin stability. Elimination of injection burden. Elimination of cold chain logistics. Enhanced iron absorption. Has Anti-inflammatory effects. ESA’s days are numbered. Amgen better get out their checkbook.
1 · Reply
Noname2022
Noname2022 Aug. 22 at 4:34 PM
Epoetin alfa (Epogen/Procrit, Q4081) pricing trend: Q3’25: $0.768/100 units Q4’25: $0.854 Q1’26: $0.774 Q2’26: $0.730 Q3’26: $0.688 Q3’25 → Q3’26: down 10.4%. Worth remembering when thinking about what “ESA-range pricing” for Vafseo actually means in 2027. $AKBA https://hcpcs.codes/q-codes/Q4081/
1 · Reply
Noname2022
Noname2022 Aug. 22 at 4:23 PM
Mircera (J0887) pricing trend: Q3’25: $1.414/mcg Q4’25: $1.465 Q1’26: $1.215 Q2’26: $1.033 Q3’26: $1.090 Q3’25 → Q3’26: down 22.9%. Something to keep in mind when thinking about what “ESA-range pricing” for Vafseo could actually mean in 2027. $AKBA https://hcpcs.codes/j-codes/J0887/
0 · Reply
Noname2022
Noname2022 Aug. 22 at 4:15 PM
$AKBA https://www.medpac.gov/wp-content/uploads/2026/03/Mar26_MedPAC_Report_To_Congress_SEC.pdf?
0 · Reply
CallMeMyBeer
CallMeMyBeer Aug. 22 at 3:56 PM
$AKBA The problem is that the tutes dont want to buy something that isn't growing. Revenue is shriveling like @MB76 gets during his circle jerk sessions with other delusionals 🤣
2 · Reply